Full access
Clinical & Research News
Published Online: 2 March 2001

FDA Approval Process Slowing

Publication: Psychiatric News
Volume 36, Number 5
https://doi.org/10.1176/pn.36.5.0033a
Track CitationsAdd to favorites
The recent lengthy review of a novel antipsychotic medication may be indicative of a trend at the U. S. Food and Drug Administration (FDA). A review of FDA files shows that the agency took almost 40 percent more time to approve new drugs during 2000 than it did the previous year. This is in stark contrast to the previous seven-year run of increasingly faster approval times.
Indeed, the apparent slowdown by federal regulators charged with approving new medications for sale has some players in the pharmaceutical industry a little concerned. However, the longer approval process may be indicative of increased scrutiny in reaction to several new drugs having been pulled from the market in recent years after patients developed unexpected and often serious side effects.
Last year the FDA approved 27 medicines that contained active ingredients never before sold in the U.S., a highly watched category of drugs the FDA calls “new molecular entities” or “NMEs.” Included in this category was the new antipsychotic ziprasidone, which received its “approvable letter” last fall, and gained final marketing clearance last month.
During 1999 the FDA approved 35 NMEs, taking an average of 12.6 months to review the approval applications. In contrast, during 2000 the 27 NMEs approved took an average of 17.6 months. Some medications, however, were approved in record short reviews of six months or fewer, including Abbot’s Kaletra to treat HIV and Pharmacia’s antibiotic Zyvox. Others took longer than 18 months, including Pfizer’s ziprasidone and Novartis AG’s Exelon for Alzheimer’s disease.
According to Alan Goldhammer, an industry analyst at the Pharmaceutical Research and Manufacturers of America (PhRMA), the slowdown was a surprise, and PhRMA is trying to determine the reasons for the change. Goldhammer suspects that approvals are slowing as FDA reviewers increasingly seek additional clinical data to document the safety and efficacy of a new product, as was the case with ziprasidone.
Although the safety of patients may be a driving concern for the slowdown, Goldhammer said that industry executives are wary, citing concerns that the slowdown results not only in delays of availability of new drugs for consumers, but also, of course, delays in revenues for the drug companies.

Information & Authors

Information

Published In

Go to Psychiatric News
Psychiatric News
Volume 36 • Number 5 • March 2, 2001
Pages: 33

History

Published online: 2 March 2001
Published in print: March 2, 2001

Authors

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard
Tips for downloading citations

View Options

View options

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share

×

As described within the American Psychiatric Association (APA)'s Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences. Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.